BackImmunityBio Overview
ImmunityBio Inc

ImmunityBio Target Price

See ImmunityBio's analyst price targets ($12) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$8.19

Average Target Price

$12.0046.5% upside

1 analysts in the last 4 months

High: $12 | Low: $12

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-05-08BTIG$1246.5% upsideOpen
2026-03-04Piper SandlerEdward Tenthoff$1246.5% upsideOpen
2026-02-23H.C. Wainwright$1583.2% upsideOpen
2026-01-20Piper Sandler$714.5% downsideOpen
2025-01-10BTIGJustin Zelin$626.7% downsideOpen
2022-08-03JefferiesKelly Shi$82.3% downsideOpen

ImmunityBio (IBRX) FAQ

The latest target price for IBRX is $12. Investors often review this figure alongside ImmunityBio's historical trend and sector peers before judging valuation or financial health.

ImmunityBio trades near $8.19 while the consensus target sits at $12 (46.5% upside). Targets are estimates based on earnings forecasts and valuation models; they change when analysts update ratings or revise models. Compare the average with the high and low targets for a fuller picture.

After noting IBRX's target price ($12), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack ImmunityBio's target price against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.